NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Kamada Ltd. (KMDA) Stock Analysis

Kamada Ltd. (KMDA) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

KMDA

$8.54

+$0.27 (+3.26%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KMDA with… →

KMDA Key Statistics

As of Sep 4, 2026
Trading
Open
$8.32
Previous Close
$8.27
Day's Range
8.32–8.60
52-Week Range
6.50–9.35
Volume
160.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.14
Valuation
Market Cap
$492.71M
P/E Ratio
21.90
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
14.31
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.62
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.57
EPS (ttm)Profit attributable to each share over the last twelve months.
0.39
Financials (FY)
Revenue (FY)
$180.46M+12.12%
Net Income (FY)
$20.20M+39.66%
Profit marginThe share of revenue left as profit after all costs and taxes.
11.60%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
57.69M
1-Year Return
+24.63%
Dividend and dates
Dividend
$0.17+2.05%
Ex-Dividend Date
August 27, 2026
Earnings Date
November 9, 2026estimated
Avg Volume
84.70K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KMDA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+24.63%
2025+19.25%
2024−0.49%
2023+52.62%
2022−39.06%
2021+1.54%
2020−5.13%
2019+36.60%
2018+5.26%
2017−12.84%
2016 (partial year)+31.33%

As of September 4, 2026.

KMDA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$180.46M$20.20M11.2%
2024$160.95M$14.46M9.0%
2023$142.52M$8.28M5.8%
2022$129.34M−$2.32M−1.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$180.46M$76.41M$26.23M$20.20M11.2%
2024$160.95M$69.97M$20.05M$14.46M9.0%
2023$142.52M$55.49M$10.06M$8.28M5.8%
2022$129.34M$46.70M$4.53M−$2.32M−1.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KMDA Dividend History

$0.20

Dividends per share, 2025 · 1 payments

YearDividends per sharePaymentsChange
2026*$0.422—
2025$0.201—

Most recent payment: $0.21 per share, ex-dividend August 27, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

KMDA Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricKMDADrug Manufacturers - Specialty & Generic medianvs median
P/E21.9019.2714% above
P/S ratio2.572.3012% above
Profit margin11.60%−3.14%14.7 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Kamada Ltd. (KMDA) at $492.71M. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 462 employees.

The 52-week range on file runs from $6.50 to $9.35. The most recent close on file for KMDA is $8.54, dated September 4, 2026. That is +$0.27 (+3.26%) against the previous close. The latest close sits 31.38% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $180.46M. Against the prior fiscal year total of $160.95M, that is a change of +12.12%. Net income for the same year was $20.20M. That is +39.66% against the prior fiscal year. Profit margin runs at 11.6%. That is 14.7 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are 0.39.

Across the 4 fiscal years on file, revenue moves from $129.34M in 2022 to $180.46M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 21.9. That is 13.68% above the Drug Manufacturers - Specialty & Generic median of 19.27. On forward earnings the ratio is 14.31. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.62. The price-to-sales ratio is 2.57. On price-to-sales that is 11.84% above the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.14. Daily returns over the trailing 10 years annualize to a volatility of 40.86%. Over the trailing twelve months the price has returned +24.63%. Measured over 10 years, that is +6.55% a year compounded.

Growth & Income

The trailing dividend yield is 2.05%. The indicated annual rate is $0.17 a share. The ex-dividend date on file is August 27, 2026. Dividends are recorded for 2 calendar years; 2026 shows 2 payments totalling $0.42 a share. The year before, 2025, totalled $0.20 a share.

2026 is still running; the price is +24.63% year to date. Across the complete calendar years on file, 2023 returned +52.62% and 2022 returned −39.06%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Kamada Ltd. (KMDA) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Kamada Ltd. KMDA $492.71M 21.9
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Kamada Ltd. trades at a P/E of 21.9.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Kamada Ltd.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Visit website →